News
Windward Bio catches $175m from its IPO

Windward Bio catches $175m from its IPO

Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.

News
Daiichi

EU clears Enhertu for HER2-low breast cancer

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

R&D

News
Windward Bio catches $175m from its IPO

Windward Bio catches $175m from its IPO

Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.

Partner Content

Partner Content
LEAP HR: Life Sciences Europe
Partner Content

LEAP HR: Life Sciences Europe

Europe’s Only Industry-Specific Meeting Advancing HR Excellence in Life Sciences